caa a22 4500 445882549 CHVBK 20180317145548.0 cr unu---uuuuu 170323e20110201xx s 000 0 eng 10.1007/s10157-010-0343-7 doi (NATIONALLICENCE)springer-10.1007/s10157-010-0343-7 Elevated serum levels of interleukin-18 in patients with overt diabetic nephropathy: effects of miglitol [Elektronische Daten] [Takashi Uzu, Hiroki Yokoyama, Hirofumi Itoh, Daisuke Koya, Atsushi Nakagawa, Makoto Nishizawa, Hiroshi Maegawa, Yukiyo Yokomaku, Shin-ichi Araki, Atsuko Abiko, Masakazu Haneda] Background: Interleukin-18 (IL-18), a pro-inflammatory cytokine, is a predictor of cardiovascular and renal disease in diabetic patients. Postprandial hyperglycemia is one of the important factors contributing to an increase in the circulating pro-inflammatory cytokine levels. This study investigated the effect of miglitol, an α-glucosidase inhibitor, on postprandial hyperglycemia and IL-18 levels in diabetic patients with nephropathy. Methods: Fifteen Japanese diabetic patients with persistent proteinuria and preserved renal function were recruited. The patients received 50mg miglitol thrice daily after the baseline examinations and were followed up for 12weeks. A meal tolerance test was performed on eight patients at baseline and week 12. The fasting miglitol concentration was measured in seven patients just before the meal tolerance test. Results: There were no changes in the body weight, blood pressure, liver and renal function, and proteinuria from baseline to week 12. However, the levels of glycated hemoglobin and interleukin 18 significantly decreased from baseline to week 12. During the meal tolerance test, plasma glucose was significantly decreased 60min after treatment with miglitol, whereas the serum concentration of insulin was not changed. Fasting and postprandial levels of IL-18 were significantly decreased from baseline to week 12. Serum miglitol concentrations showed a significantly negative correlation with eGFR (r=−0.82, p=0.02). However, the serum miglitol concentrations did not changed during the course of this study. Conclusion: Miglitol improved postprandial hyperglycemia and reduced serum IL-18 levels in patients with stage 3 diabetic nephropathy. Miglitol may therefore prevent atherosclerotic diseases and diabetic micro-vascular complications through decreasing glucose swings and/or the circulating IL-18 level. Japanese Society of Nephrology, 2010 Proinflammatory cytokine nationallicence Postprandial nationallicence Hyperglycemia nationallicence Diabetic nephropathy nationallicence α-Glucosidase inhibitors nationallicence Uzu Takashi Department of Medicine, Shiga University of Medical Science, 520-2192, Otsu, Shiga, Japan aut Yokoyama Hiroki Internal Medicine, Jiyugaoka Medical Clinic, Obihiro, Hokkaido, Japan aut Itoh Hirofumi Internal Medicine, Jiyugaoka Medical Clinic, Obihiro, Hokkaido, Japan aut Koya Daisuke Division of Diabetes & Endocrinology, Department of Medicine, Kanazawa Medical University, Kahoku-gun, Ishikawa, Japan aut Nakagawa Atsushi Division of Diabetes & Endocrinology, Department of Medicine, Kanazawa Medical University, Kahoku-gun, Ishikawa, Japan aut Nishizawa Makoto Division of Diabetes & Endocrinology, Department of Medicine, Kanazawa Medical University, Kahoku-gun, Ishikawa, Japan aut Maegawa Hiroshi Department of Medicine, Shiga University of Medical Science, 520-2192, Otsu, Shiga, Japan aut Yokomaku Yukiyo Department of Medicine, Shiga University of Medical Science, 520-2192, Otsu, Shiga, Japan aut Araki Shin-ichi Department of Medicine, Shiga University of Medical Science, 520-2192, Otsu, Shiga, Japan aut Abiko Atsuko Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan aut Haneda Masakazu Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan aut Clinical and Experimental Nephrology Springer Japan 15/1(2011-02-01), 58-63 1342-1751 15:1<58 2011 15 10157 https://doi.org/10.1007/s10157-010-0343-7 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10157-010-0343-7 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Uzu Takashi Department of Medicine, Shiga University of Medical Science, 520-2192, Otsu, Shiga, Japan aut NATIONALLICENCE 700 1- Yokoyama Hiroki Internal Medicine, Jiyugaoka Medical Clinic, Obihiro, Hokkaido, Japan aut NATIONALLICENCE 700 1- Itoh Hirofumi Internal Medicine, Jiyugaoka Medical Clinic, Obihiro, Hokkaido, Japan aut NATIONALLICENCE 700 1- Koya Daisuke Division of Diabetes & Endocrinology, Department of Medicine, Kanazawa Medical University, Kahoku-gun, Ishikawa, Japan aut NATIONALLICENCE 700 1- Nakagawa Atsushi Division of Diabetes & Endocrinology, Department of Medicine, Kanazawa Medical University, Kahoku-gun, Ishikawa, Japan aut NATIONALLICENCE 700 1- Nishizawa Makoto Division of Diabetes & Endocrinology, Department of Medicine, Kanazawa Medical University, Kahoku-gun, Ishikawa, Japan aut NATIONALLICENCE 700 1- Maegawa Hiroshi Department of Medicine, Shiga University of Medical Science, 520-2192, Otsu, Shiga, Japan aut NATIONALLICENCE 700 1- Yokomaku Yukiyo Department of Medicine, Shiga University of Medical Science, 520-2192, Otsu, Shiga, Japan aut NATIONALLICENCE 700 1- Araki Shin-ichi Department of Medicine, Shiga University of Medical Science, 520-2192, Otsu, Shiga, Japan aut NATIONALLICENCE 700 1- Abiko Atsuko Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan aut NATIONALLICENCE 700 1- Haneda Masakazu Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, Japan aut NATIONALLICENCE 773 0- Clinical and Experimental Nephrology Springer Japan 15/1(2011-02-01), 58-63 1342-1751 15:1<58 2011 15 10157 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer